Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis

References

• Herrman H, Kieling C, McGorry P, et al., Reducing the global burden of depression: a lancet–world psychiatric association commission. Lancet. 393(10189): e42–e43. 2019. . 10.1016/S0140-6736(18)32408-5.
   PubMed Web of Science ®Google Scholar
• Charlson F, van OM, Flaxman A, et al. New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. Lancet. 2019;394(10194):240–248. DOI:10.1016/S0140-6736(19)30934-1.
   PubMed Web of Science ®Google Scholar
• Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–659.
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Lux L, Gartlehner G, et al., Defining treatment-resistant depression. Depress Anxiety. 37(2): 134–145. 2020. . 10.1002/da.22968.
   PubMed Web of Science ®Google Scholar
• Trevino K, McClintock SM, McDonald Fischer N, et al. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr. 2014;26:222–232.
   Google Scholar
• Shah AA. Novel approaches for managing treatment-resistant depression. Psychiatr Ann. 2016;46(4):220–222.
   Web of Science ®Google Scholar
• Thomas L, Kessler D, Campbell J, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract J R Coll Gen Pract. 2013;63(617):e852–858. DOI:10.3399/bjgp13X675430.
   PubMed Web of Science ®Google Scholar
• Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019;13:3051–3067.
   PubMed Web of Science ®Google Scholar
• Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. Internet]. 2016 [cited 2019 Dec 10];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126726/
   Web of Science ®Google Scholar
• Maeng S, Zarate CA. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep. 2007;9(6):467–474.
   PubMedGoogle Scholar
• Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231(18):3663–3676. DOI:10.1007/s00213-014-3664-5.
   PubMed Web of Science ®Google Scholar
• Han Y, Chen J, Zou D, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat. 2016;12:2859–2867.
   PubMed Web of Science ®Google Scholar
• Lee EE, Della Selva MP, Liu A, et al. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):178–184. DOI:10.1016/j.genhosppsych.2015.01.003.
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693–704. DOI:10.1017/S0033291714001603.
   PubMed Web of Science ®Google Scholar
• Xu Y, Hackett M, Carter G, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2016;19(4): pyv124. DOI:10.1093/ijnp/pyv124.
   Web of Science ®Google Scholar
• Wilkinson ST, Ballard ED, Bloch MH, et al., The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 175(2): 150–158. 2018. . 10.1176/appi.ajp.2017.17040472.
   PubMed Web of Science ®Google Scholar
• Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54(1):29–45. DOI:10.1177/0004867419883341.
   PubMed Web of Science ®Google Scholar
• Xiong J, Lipsitz O, Chen-Li D, et al. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis. J Psychiatr Res. 2021;134:57–68.
   PubMed Web of Science ®Google Scholar
• Alberich S, Martínez-Cengotitabengoa M, López P, et al. Efficacy and safety of ketamine in bipolar depression: a systematic review. Rev Psiquiatr Salud Ment. 2017;10:104–112.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Vande Voort JL, Croarkin PE, et al. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety. 2016;33(8):698–710. DOI:10.1002/da.22505.
   PubMed Web of Science ®Google Scholar
• Ortiz R, Niciu MJ, Lukkahati N, et al. Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord. 2015;172:307–311.
   PubMed Web of Science ®Google Scholar
• Romeo B, Choucha W, Fossati P, et al. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015;230(2):682–688. DOI:10.1016/j.psychres.2015.10.032.
   PubMed Web of Science ®Google Scholar
• Rong C, Park C, and Rosenblat JD, et al. Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J Environ Res Public Health. 2018;15(4):1–10.
   Web of Science ®Google Scholar
• Sienaert P, Lambrichts L, Dols A, et al. Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipolar Disord. 2013;15(1):61–69. DOI:10.1111/bdi.12026.
   PubMed Web of Science ®Google Scholar
• Villaseñor A, Ramamoorthy A, Dos SMS, et al. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br J Pharmacol. 2014;171(8):2230–2242. DOI:10.1111/bph.12494.
   PubMed Web of Science ®Google Scholar
• Zhao X, Venkata SLV, Moaddel R, et al. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol. 2012;74(2):304–314. DOI:10.1111/j.1365-2125.2012.04198.x.
   PubMed Web of Science ®Google Scholar
• Fernie G, Currie J, Perrin JS, et al. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial. Br J Psychiatry. 2017;210(6):422–428. DOI:10.1192/bjp.bp.116.189134.
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Fasula M, Kelmendi B, et al. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT. 2012;28(3):157–161. DOI:10.1097/YCT.0b013e31824f8296.
   PubMed Web of Science ®Google Scholar
• Ainsworth NJ, Sepehry AA, Vila-Rodriguez F. Effects of ketamine anesthesia on efficacy, tolerability, seizure response, and neurocognitive outcomes in electroconvulsive therapy: a comprehensive meta-analysis of double-blind randomized controlled trials. J ECT. 2020;36(2):94–105.
   PubMed Web of Science ®Google Scholar
• Anderson IM, Blamire A, Branton T, et al. Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry. 2017;4(5):365–377. DOI:10.1016/S2215-0366(17)30077-9.
   PubMed Web of Science ®Google Scholar
• Chen Q, Min S, Hao X, et al. Effect of low dose of ketamine on learning memory function in patients undergoing electroconvulsive therapy-A randomized, double-blind, controlled clinical study. J ECT. 2017;33(2):89–95. DOI:10.1097/YCT.0000000000000365.
   PubMed Web of Science ®Google Scholar
• Dong J, Min S, Qiu H, et al. Intermittent administration of low dose ketamine can shorten the course of electroconvulsive therapy for depression and reduce complications: a randomized controlled trial. Psychiatry Res. 2019;281:112573.
   PubMed Web of Science ®Google Scholar
• Gamble JJ, Bi H, Bowen R, et al. Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study. Can J Anesth Can Anesth. 2018;65(6):636–646. DOI:10.1007/s12630-018-1088-0.
   Google Scholar
• Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. 2014;215(2):355–361. DOI:10.1016/j.psychres.2013.12.008.
   PubMed Web of Science ®Google Scholar
• Järventausta K, Chrapek W, Kampman O, et al. Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J Ect. 2013;29(3):158–161. DOI:10.1097/YCT.0b013e318283b7e9.
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. J Psychiatr Res. 2015;62:23–30.
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, et al. Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis. Br J Psychiatry J Ment Sci. 2017;210(6):403–407. DOI:10.1192/bjp.bp.116.195826.
   PubMed Web of Science ®Google Scholar
• Rasmussen KG, Kung S, Lapid MI, et al. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014;215(2):362–365. DOI:10.1016/j.psychres.2013.12.027.
   PubMed Web of Science ®Google Scholar
• Ray-Griffith SL, Eads LA, Han X, et al. A randomized pilot study comparing ketamine and methohexital anesthesia for electroconvulsive therapy in patients with depression. J ECT. 2017;33(4):268–271. DOI:10.1097/YCT.0000000000000413.
   PubMed Web of Science ®Google Scholar
• Salehi B, Mohammadbeigi A, Kamali AR, et al. Impact comparison of ketamine and sodium thiopental on anesthesia during electroconvulsive therapy in major depression patients with drug-resistant; a double-blind randomized clinical trial. Ann Card Anaesth. 2015;18(4):486. DOI:10.4103/0971-9784.166444.
   PubMedGoogle Scholar
• Wang X, Chen Y, Zhou X, et al. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT. 2012;28(2):128–132. DOI:10.1097/YCT.0b013e31824d1d02.
   PubMed Web of Science ®Google Scholar
• Wojdacz R, Swiecicki L, Antosik-Wojcinska A. Comparison of the effect of intravenous anesthetics used for anesthesia during electroconvulsive therapy on the hemodynamic safety and the course of ECT [review]. Psychiatr Pol. 2017;51(6):1039–1058.
   PubMed Web of Science ®Google Scholar
• Yoosefi A, Sepehri AS, Kargar M, et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. J ECT. 2014;30(1):15–21. DOI:10.1097/YCT.0b013e3182a4b4c6.
   PubMed Web of Science ®Google Scholar
• Zhang M, Rosenheck R, Lin X, et al. A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. J Affect Disord. 2018;1:372–378.
   Google Scholar
• Zheng W, X-h L, Zhu X-M, et al. Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: a meta-analysis of randomized controlled trials. J Affect Disord. 2019;250:123–131.
   PubMed Web of Science ®Google Scholar
• Zhong X, He H, Zhang C, et al. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression. J Affect Disord. 2016;201:124–130.
   PubMed Web of Science ®Google Scholar
• Shams Alizadeh N, Maroufi A, Nasseri K, et al. Antidepressant effect of combined ketamine and electroconvulsive therapy on patients with major depressive disorder: a randomized trial. Iran J Psychiatry Behav Sci. 2015;9(3):e1578. DOI:10.17795/ijpbs-1578.
   PubMedGoogle Scholar
• Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2012;37(6):1526–1533. DOI:10.1038/npp.2011.338.
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Murrough JW, aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82. DOI:10.1017/S1461145709000169.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430–432. Benoit B Berman, De Sarro, First, Frizzo, Hebert, Lacomblez, Maj, Montgomery, Paul, Tonen, Wagner, Wang, Young, Zarate, Zarate, Zarate, editor. DOI:10.1016/j.biopsych.2004.11.023.
   PubMed Web of Science ®Google Scholar
• Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev [Internet]. 2015 [cited 2019 Dec 1]; Available from: http://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011612.pub2/full.
   Google Scholar
• McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015; CD011611. DOI:10.1002/14651858.CD011611.pub2.
   Web of Science ®Google Scholar
• Chen M-H, Cheng C-M, Gueorguieva R, et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2019;44(12):2112–2118. DOI:10.1038/s41386-019-0480-y.
   PubMed Web of Science ®Google Scholar
• Pickering G, Pereira B, Morel V, et al. Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients. Contemp Clin Trials. 2014;38(2):314–320. DOI:10.1016/j.cct.2014.06.004.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19(9):978–985. DOI:10.1038/mp.2013.130.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73(10):613–627.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol. 2020;177:113935.
   PubMed Web of Science ®Google Scholar
• Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370–380.
   PubMed Web of Science ®Google Scholar
• Wei Y, Chang L, Hashimoto K. A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav. 2020;190:172870.
   PubMed Web of Science ®Google Scholar
• Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801–811.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hashimoto K. An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother. 2019;19(1):83–92.
   PubMed Web of Science ®Google Scholar
• Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol Oxf Engl. 2021;35(2):109–123.
   PubMed Web of Science ®Google Scholar
• Dold M, Bartova L, Kasper S. Treatment response of add-on esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic treatment. Int J Neuropsychopharmacol. 2020;23(7):440–445.
   PubMed Web of Science ®Google Scholar
• Zheng W, Cai D-B, Xiang Y-Q, et al. Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord. 2020;265:63–70.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Salloum NC, Hock RS, et al., Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry. 81(19): r12889. 2020. . 10.4088/JCP.19r12889.
   Google Scholar
• Leal GC, Bandeira ID, Correia-Melo FS, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2021;271(3):577–582. DOI:10.1007/s00406-020-01110-5.
   PubMed Web of Science ®Google Scholar
• Zanos P, Highland JN, Liu X, et al. (R)-ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Br J Pharmacol. 2019;176(14):2573–2592. DOI:10.1111/bph.14683.
   PubMed Web of Science ®Google Scholar
• Zanos P, Thompson SM, Duman RS, et al. Convergent mechanisms underlying rapid antidepressant action. CNS Drugs. 2018;32(3):197–227. DOI:10.1007/s40263-018-0492-x.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70(3):621–660. DOI:10.1124/pr.117.015198.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–486. DOI:10.1038/nature17998.
   PubMed Web of Science ®Google Scholar
• Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172(10):950–966. DOI:10.1176/appi.ajp.2015.15040465.
   PubMed Web of Science ®Google Scholar
• Burger J, Capobianco M, Lovern R, et al. A double-blinded, randomized, placebo-controlled sub-dissociative dose ketamine pilot study in the treatment of acute depression and suicidality in a military emergency department setting. Mil Med. 2016;181(10):1195–1199. DOI:10.7205/MILMED-D-15-00431.
   PubMed Web of Science ®Google Scholar
• Lener MS, Kadriu B, Zarate CA. Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression. Drugs. 2017;77(4):381–401.
   PubMed Web of Science ®Google Scholar
• Bahji A, Vazquez GH, and Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–555.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Med. 2009;6(7):e1000100. DOI:10.1371/journal.pmed.1000100.
   PubMed Web of Science ®Google Scholar
• Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(7):535–541.*. of interest for a systematic meta analysis review on ketamine for BD. DOI:10.1093/ijnp/pyab023.
   PubMed Web of Science ®Google Scholar
• Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia; 2019.
   Google Scholar
• Bahji A, Vazquez GH, Zarate CA. Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: putting the cart before the horse? J Affect Disord. 2021;282:258–260.
   PubMed Web of Science ®Google Scholar
• Bahji A, Vazquez GH, Zarate CA. Erratum to” comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis”. [journal of affective disorders 278C (2021) 542-555] J Affect Disord. 2021;281(281):1001.
   PubMedGoogle Scholar
• Drevets WC, Popova V, Daly EJ, et al. Comments to Drs. Bahji, Vazquez, and Zarate. J Affect Disord. 2021;283:262–264.
   PubMed Web of Science ®Google Scholar
• Ekstrand J. Letter to the editor: comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;289:88–89.
   PubMed Web of Science ®Google Scholar
• Souza-Marques B, Mello RP, Jesus-Nunes AP, et al. Letter to the editor - comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;283:265–266.
   PubMed Web of Science ®Google Scholar
• Cochrane Collaboration. Cochrane handbook: general methods for cochrane reviews. [Internet]. Heterogeneity. 2014 [cited 2019 Jul 17]. Available from: https://handbook-5-1.cochrane.org/chapter_9/9_5_heterogeneity.htm.
   Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Bahji A, Ermacora D, Stephenson C, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2020;269:154–184.
   PubMed Web of Science ®Google Scholar
• Bahji A, Ermacora D, Stephenson C, et al. Comparative efficacy and tolerability of adjunctive pharmacotherapies for acute bipolar depression: a systematic review and network meta-analysis. Can J Psychiatry Rev Can Psychiatr. 2021;66(3):274–288. DOI:10.1177/0706743720970857.
   PubMed Web of Science ®Google Scholar
• Vázquez GH, Bahji A, Undurraga J, et al. Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. Lithium J Psychopharmacol Oxf Engl. 2021;35:890–900. DOI:10.1177/02698811211013579
   PubMed Web of Science ®Google Scholar
• Schwarzer G. meta: an R package for meta-analysis [Internet]. USA: R; 2007 [cited 2019 Nov 3]. Available from: https://cran.r-project.org/web/packages/meta/meta.pdf.
   Google Scholar
• Ionescu DF, Bentley KH, Eikermann M, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial. J Affect Disord. 2019;243:516–524.
   PubMed Web of Science ®Google Scholar
• Phillips JL, Norris S, Talbot J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176(5):401–409. DOI:10.1176/appi.ajp.2018.18070834.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826. DOI:10.1176/appi.ajp.2016.16010037.
   PubMed Web of Science ®Google Scholar
• C-T L, Chen M-H, Lin W-C, et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp. 2016;37:1080–1090.
   PubMed Web of Science ®Google Scholar
• Arabzadeh S, Hakkikazazi E, Shahmansouri N, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord. 2018;235:236–241.
   PubMed Web of Science ®Google Scholar
• George D, Gálvez V, Martin D, et al. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatr Psychiatry. 2017;25(11):1199–1209. DOI:10.1016/j.jagp.2017.06.007.
   PubMed Web of Science ®Google Scholar
• Loo CK, Gálvez V, O’Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134(1):48–56. DOI:10.1111/acps.12572.
   PubMed Web of Science ®Google Scholar
• Lapidus KAB, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970–976. DOI:10.1016/j.biopsych.2014.03.026.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–148. DOI:10.1001/jamapsychiatry.2017.3739.
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630. DOI:10.1176/appi.ajp.2018.17060720.
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438. DOI:10.1176/appi.ajp.2019.19020172.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80(6):424–431. DOI:10.1016/j.biopsych.2015.10.018.
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Leal GC, Vieira F, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527–534.
   PubMed Web of Science ®Google Scholar
• Cao Z, Lin C-T, Ding W, et al. Identifying ketamine responses in treatment-resistant depression using a wearable forehead EEG. IEEE Trans Biomed Eng. 2019;66(6):1668–1679. DOI:10.1109/TBME.2018.2877651.
   PubMed Web of Science ®Google Scholar
• Chen M-H, C-T L, Lin W-C, et al. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion. J Affect Disord. 2018;241:1–7.
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802. DOI:10.1001/archgenpsychiatry.2010.90. .
   PubMed Web of Science ®Google Scholar
• Domany Y, Shelton RC, McCullumsmith CB. Ketamine for acute suicidal ideation. An emergency department intervention: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Depress Anxiety [Internet]. 2019 [cited 2020 Jan 2];n/a. Available from: http://onlinelibrary.wiley.com/doi/abs/10.1002/da.22975.
   Google Scholar
• Downey D, Dutta A, McKie S, et al. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2016;26(6):994–1003. DOI:10.1016/j.euroneuro.2016.03.006.
   PubMed Web of Science ®Google Scholar
• Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018;25(7):1592–1603. DOI:10.1038/s41380-018-0256-5.
   PubMed Web of Science ®Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–630. DOI:10.1093/ijnp/pyz039.
   PubMed Web of Science ®Google Scholar
• Fu D-J, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. Internet]. 2020 [cited 2020 Dec 29];81. Available from. ;(3). https://www.psychiatrist.com/JCP/article/Pages/2020/v81/19m13191.aspx
   PubMed Web of Science ®Google Scholar
• Gálvez V, Li A, Huggins C, et al. Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol (Oxf). 2018;32(4):397–407. DOI:10.1177/0269881118760660.
   PubMed Web of Science ®Google Scholar
• Grunebaum MF, Ellis SP, Keilp JG, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017;19(3):176–183. DOI:10.1111/bdi.12487.
   PubMed Web of Science ®Google Scholar
• Grunebaum MF, Galfalvy HC, Choo T-H, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. DOI:10.1176/appi.ajp.2017.17060647.
   PubMed Web of Science ®Google Scholar
• Y-d H, Xiang Y-T, Fang J-X, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016;46:623–635.
   PubMed Web of Science ®Google Scholar
• Ionescu DF, D-J F, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22–31.*. of interest on the safety and efficacy of IN Esketamine for severe MDD with active suicidal risks. DOI:10.1093/ijnp/pyaa068.
   PubMed Web of Science ®Google Scholar
• Lai R, Katalinic N, Glue P, et al. Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry. 2014;15(7):579–584. DOI:10.3109/15622975.2014.922697.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571–3580. DOI:10.1017/S0033291715001506.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142. DOI:10.1176/appi.ajp.2013.13030392.
   PubMed Web of Science ®Google Scholar
• Nugent AC, Ballard E, Gould TD, et al. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry. 2019;24(7):1040–1052. DOI:10.1038/s41380-018-0028-2.
   PubMed Web of Science ®Google Scholar
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28(2):121–141. DOI:10.1016/j.jagp.2019.10.008.
   PubMed Web of Science ®Google Scholar
• Šóš P, Klírová M, Novak T, et al. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 2013;34(4):287–293.
   PubMed Web of Science ®Google Scholar
• T-P S, Chen M-H, C-T L, et al. Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42(13):2482–2492. DOI:10.1038/npp.2017.94.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–946.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. DOI:10.1001/archpsyc.63.8.856.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. DOI:10.1016/S0006-3223(99)00230-9.
   PubMed Web of Science ®Google Scholar
• Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019;214(1):20–26. DOI:10.1192/bjp.2018.196.
   PubMed Web of Science ®Google Scholar
• Li M, Demenescu LR, Colic L, et al. Temporal dynamics of antidepressant ketamine effects on glutamine cycling follow regional fingerprints of AMPA and NMDA receptor densities. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2017;42(6):1201–1209. DOI:10.1038/npp.2016.184.
   PubMed Web of Science ®Google Scholar
• Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci JPN. 2017;42:222–229.
   PubMed Web of Science ®Google Scholar
• Zorumski CF, Izumi Y, Mennerick SK. NMDA receptors and beyond. J Neurosci. 2016;36:11158–11164.
   PubMed Web of Science ®Google Scholar
• Evans JW, Szczepanik J, Brutsche N, et al. Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration. Biol Psychiatry. 2018;84(8):582–590. DOI:10.1016/j.biopsych.2018.01.027.
   PubMed Web of Science ®Google Scholar
• Strasburger SE, Bhimani PM, Kaabe JH, et al. What is the mechanism of ketamine’s rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. J Clin Pharm Ther. 2017;42:147–154.
   PubMed Web of Science ®Google Scholar
• Bonaventura J, Lam S, Carlton M, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. 2021;26(11):6704–6722. DOI:10.1038/s41380-021-01093-2.
   PubMed Web of Science ®Google Scholar
• López-Díaz Á, Fernández-González JL, Luján-Jiménez JE, et al. Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain. Ther Adv Psychopharmacol. 2017;7(4):137–140. DOI:10.1177/2045125316675578.
   PubMed Web of Science ®Google Scholar
• Gałuszko-Węgielnik M, Wiglusz MS, Słupski J, et al. Efficacy of ketamine in bipolar depression: focus on anhedonia. Psychiatria Danubina. 2019;31(Suppl 3):554–560.
   PubMedGoogle Scholar
• Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2015;17(4):438–443. DOI:10.1111/bdi.12277.
   PubMed Web of Science ®Google Scholar
• Kraus C, Rabl U, Vanicek T, et al. Administration of ketamine for unipolar and bipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):2–12. DOI:10.1080/13651501.2016.1254802.
   PubMed Web of Science ®Google Scholar